Index S&P 500
P/E 29.14
EPS (ttm) 7.48
Insider Own 0.29%
Shs Outstand 88.20M
Perf Week 1.77%
Market Cap 18.50B
Forward P/E 14.93
EPS next Y 14.59
Insider Trans -2.61%
Shs Float 84.65M
Perf Month 3.98%
Income 661.20M
PEG -
EPS next Q 3.26
Inst Own 98.59%
Short Float / Ratio 3.64% / 3.75
Perf Quarter 6.15%
Sales 13.54B
P/S 1.37
EPS this Y -20.66%
Inst Trans -2.81%
Short Interest 3.08M
Perf Half Y 15.01%
Book/sh 92.73
P/B 2.35
EPS next Y 7.36%
ROA 3.42%
Target Price 241.54
Perf Year 7.28%
Cash/sh 8.57
P/C 25.41
EPS next 5Y -3.18%
ROE 6.98%
52W Range 179.58 - 222.76
Perf YTD 7.70%
Dividend 1.82
P/FCF 18.55
EPS past 5Y 3.41%
ROI 5.07%
52W High -2.20%
Beta 1.05
Dividend % 0.83%
Quick Ratio 1.20
Sales past 5Y 8.10%
Gross Margin 25.11%
52W Low 21.32%
ATR 3.42
Employees 80000
Current Ratio 1.36
Sales Q/Q -15.23%
Oper. Margin 9.45%
RSI (14) 63.35
Volatility 1.94% 1.38%
Optionable Yes
Debt/Eq 0.80
EPS Q/Q -45.84%
Profit Margin 4.88%
Rel Volume 0.63
Prev Close 217.02
Shortable Yes
LT Debt/Eq 0.66
Earnings Oct 26 BMO
Payout 15.47%
Avg Volume 821.66K
Price 217.87
Recom 1.69
SMA20 3.05%
SMA50 5.95%
SMA200 7.68%
Volume 521,481
Change 0.39%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-06-23 Initiated
HSBC Securities
Hold
$210
Dec-12-22 Downgrade
Citigroup
Buy → Neutral
$275 → $250
Sep-19-22 Downgrade
Argus
Buy → Hold
Aug-22-22 Resumed
Morgan Stanley
Overweight
$300
Jan-28-22 Downgrade
Deutsche Bank
Buy → Hold
$330 → $294
Jan-11-21 Upgrade
Argus
Hold → Buy
$245
Jan-11-21 Downgrade
Wolfe Research
Peer Perform → Underperform
Jan-08-21 Downgrade
Wolfe Research
Outperform → Peer Perform
Jul-14-20 Upgrade
BofA Securities
Neutral → Buy
$194 → $220
Jul-13-20 Upgrade
Wolfe Research
Peer Perform → Outperform
Jun-02-20 Resumed
Deutsche Bank
Buy
$210
May-15-20 Upgrade
Mizuho
Neutral → Buy
$158 → $186
Apr-29-20 Downgrade
KeyBanc Capital Markets
Overweight → Sector Weight
Apr-27-20 Upgrade
Wolfe Research
Underperform → Peer Perform
Apr-27-20 Upgrade
Citigroup
Neutral → Buy
$204 → $214
Jan-08-20 Initiated
Wells Fargo
Overweight
$210
Jul-16-19 Upgrade
BofA/Merrill
Underperform → Neutral
Jun-21-19 Upgrade
Deutsche Bank
Hold → Buy
$180 → $220
Apr-02-19 Upgrade
Jefferies
Hold → Buy
$154 → $190
Jan-17-19 Initiated
UBS
Buy
$169
Show Previous Ratings
Nov-30-23 07:46PM
Nov-27-23 08:35AM
Nov-24-23 07:21AM
Nov-22-23 05:04AM
Nov-20-23 07:00AM
07:00AM
Loading…
Nov-16-23 07:00AM
Nov-08-23 07:00AM
Nov-06-23 05:07AM
Oct-31-23 01:17AM
Oct-28-23 02:29PM
Oct-27-23 08:30AM
08:30AM
Oct-26-23 11:13PM
(Thomson Reuters StreetEvents)
04:19PM
02:51PM
(American City Business Journals)
10:36AM
Loading…
10:36AM
09:30AM
08:48AM
08:15AM
08:08AM
07:06AM
(Associated Press Finance)
06:58AM
Oct-23-23 06:26AM
Oct-19-23 10:01AM
Oct-16-23 08:30PM
(The Wall Street Journal)
Oct-13-23 08:28AM
Oct-12-23 06:56AM
Oct-11-23 08:30AM
07:30AM
Oct-05-23 10:08AM
04:25PM
Loading…
Oct-04-23 04:25PM
Sep-29-23 06:57AM
Sep-28-23 09:06AM
Sep-27-23 11:15AM
Sep-19-23 07:20AM
05:00AM
Sep-14-23 06:56AM
Sep-11-23 07:45PM
Sep-04-23 12:06PM
Aug-28-23 10:40AM
Aug-17-23 09:26PM
Aug-15-23 05:38AM
(American City Business Journals)
Aug-14-23 03:15PM
(The Wall Street Journal)
Aug-08-23 04:05PM
Aug-07-23 09:57AM
09:57AM
Aug-03-23 02:56PM
(American City Business Journals)
08:35AM
07:00AM
Jul-31-23 06:57AM
Jul-28-23 02:15PM
02:48AM
(Thomson Reuters StreetEvents)
Jul-27-23 03:24PM
02:31PM
(American City Business Journals)
02:24PM
01:00PM
11:38AM
08:44AM
08:41AM
07:09AM
06:57AM
02:00AM
Jul-26-23 11:04AM
Jul-24-23 04:27PM
07:22AM
Jul-20-23 10:02AM
Jul-19-23 12:14PM
Jul-17-23 09:13AM
Jul-13-23 08:00AM
06:58AM
Jul-11-23 03:01PM
(American City Business Journals)
07:00AM
Jul-07-23 12:00PM
(The Wall Street Journal)
Jul-03-23 07:05AM
06:57AM
Jun-29-23 09:58PM
07:02AM
Jun-28-23 06:08PM
Jun-14-23 08:59AM
Jun-12-23 06:30PM
05:28PM
11:18AM
Jun-09-23 05:18PM
04:51PM
04:43PM
Jun-08-23 09:08AM
Jun-07-23 01:18PM
07:00AM
Jun-05-23 06:57AM
Jun-02-23 12:56PM
12:41PM
Jun-01-23 08:39AM
May-31-23 04:35PM
May-26-23 06:52AM
06:32AM
May-25-23 11:30AM
May-17-23 02:15PM
May-16-23 02:32PM
10:59AM
07:00AM
Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Wilkinson Peter J SVP, Chief Accounting Officer Nov 16 Sale 210.71 1,384 291,627 2,087 Nov 20 12:23 PM ANDERSON KERRII B Director Aug 08 Sale 211.57 5,000 1,057,832 15,275 Aug 10 08:55 AM van der Vaart Sandra D EVP, Chief Legal Officer Jun 29 Sale 240.00 212 50,880 7,605 Jul 03 11:52 AM Kirchgraber Paul R CEO, Covance Drug Development May 19 Option Exercise 182.51 4,300 784,793 17,246 May 23 08:06 AM Kirchgraber Paul R CEO, Covance Drug Development May 19 Sale 216.91 4,300 932,707 12,946 May 23 08:06 AM Schroeder Mark S EVP, Pres Diagnostics & COO May 18 Option Exercise 130.60 1,500 195,900 8,187 May 22 03:08 PM Schroeder Mark S EVP, Pres Diagnostics & COO May 18 Sale 216.77 1,500 325,155 6,687 May 22 03:08 PM Schroeder Mark S EVP, President-Diagnostics Lab Mar 31 Sale 225.81 3,897 879,982 6,687 Apr 03 10:05 AM Kirchgraber Paul R CEO, Covance Drug Development Feb 21 Option Exercise 182.51 3,000 547,530 17,069 Feb 23 09:54 AM Kirchgraber Paul R CEO, Covance Drug Development Feb 21 Sale 250.58 8,000 2,004,675 9,069 Feb 23 09:54 AM Schroeder Mark S EVP, President-Diagnostics Lab Feb 14 Sale 247.63 309 76,518 6,687 Feb 16 12:51 PM Schroeder Mark S EVP, President-Diagnostics Lab Feb 07 Sale 243.01 409 99,391 6,687 Feb 09 09:04 AM van der Vaart Sandra D EVP, Chief Legal Officer Feb 07 Sale 243.01 219 53,219 5,341 Feb 09 09:27 AM Schroeder Mark S EVP, President-Diagnostics Lab Feb 03 Sale 253.90 324 82,264 6,687 Feb 06 03:51 PM van der Vaart Sandra D EVP, Chief Legal Officer Feb 03 Sale 253.90 173 43,925 5,341 Feb 06 03:56 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite